More Osteoporosis Patients Gained Bone on Abaloparatide Than on Teriparatide or Placebo

Prospective, exploratory responder analysis from the ACTIVE phase 3 trial (NCT01343004). Postmenopausal women with osteoporosis were randomized to abaloparatide, teriparatide, or placebo for 18 months. BMD was measured at total hip, femoral neck, and lumbar spine at 6, 12, and 18 months. Responders were defined as patients achieving BMD gains at all three sites simultaneously.

For postmenopausal women with severe osteoporosis, not just average bone density gain matters — what matters is what proportion of patients actually respond well to treatment. This analysis shows that abaloparatide produces meaningful bone density improvement in a larger proportion of patients than teriparatide (the existing peptide standard). Since abaloparatide is a 34-amino-acid peptide that selectively targets a specific conformation of the PTH receptor, it represents a next-generation peptide approach to bone building.

Abaloparatide and teriparatide are both peptide drugs that build bone by activating the PTH1 receptor, but abaloparatide does so by preferentially binding a specific receptor conformation (RG) that promotes bone building over bone resorption. This responder analysis supports abaloparatide's clinical edge and helps clinicians choose between the two available bone-building peptide options for high-risk osteoporosis patients.

This is an exploratory (not pre-specified primary) analysis of the ACTIVE trial. The responder definition requiring gains at all three sites is stringent and may not reflect clinical significance at individual sites. The trial was industry-sponsored (Radius Health, maker of abaloparatide). The study enrolled only postmenopausal women, so results may not generalize to men or premenopausal osteoporosis.